Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase ...
Financial messaging co-operative Swift is reporting a succesful community migration from legacy message type (MT) 100 to the new MT103, which holds out the promise of increased automation and ...
Several antibodies in Micromet's product pipeline are BiTE antibodies and have been generated based on Micromet's proprietary BiTE antibody platform. The most advanced BiTE antibody is MT103 (MEDI-538 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback